Triamcinolone Acetonide Inhibits Neovascularization in an ROP Mouse Model in vivo and in vitro
Spandau U. H. M.1, Sauder G.1, Schubert U.2, Hammes H.-P.3
1Department of Ophthalmology and 3Department. of Internal Medicine, Faculty of Clinical Medicine Mannheim, Ruprecht-Karls-University of Heidelberg, Germany; 2Institute of Biochemistry, University of Giessen, Germany
Purpose: To evaluate the effect of crystalline triamcinolone acetonide on proliferating retinal endothelial cells in vivo and in vitro.
Method: Using bovine retinal endothelial cells, a sprouting assay with different concentrations of crystalline triamcinolone acetonide was performed. For in vivo analysis, a retinopathy of prematurity (ROP) model was used. Sixteen C57BL/J6 mice were exposed to 75% oxygen from postnatal day 7 to day 12 . On day 12, crystalline triamcinolone acetonide was intravitreally injected into one eye (study eye), and isotonic saline into the contralateral eye (control eye). On day 17, the mice were sacrificed and the eyes removed for quantitative analysis of preretinal neovascularizations. Four non-exposed mice served as negative control. Immuno-histochemistry was used to detect inflammatory changes in ROP lesions.
Results: In vitro sprouting assay revealed a dose-dependent inhibition of bovine retinal endothelial cells from 0.05 mg triamcinolone/ml (no inhibition) to 2 mg triamcinolone/ml (complete inhibition). The ROP model demo
Zurück | Back